Tempus reports Q2 2026 revenue of $382.5 million, up 22%, as it projects long-term growth tied to diagnostic platforms.
Tempus AI announced a 2026 revenue target of $1.595 billion to $1.605 billion during its Q2 2026 earnings call. The company also outlined plans for a $400 million uplift by 2028, driven by its xT CDx and xF platforms.
Revenue for Q2 2026 reached $382.5 million, a 22% increase year-over-year, marking the first quarter with Ambry fully integrated into results. The company highlighted strong growth momentum as it scales its diagnostic and data-driven healthcare solutions.
Management emphasized the strategic focus on expanding its platform capabilities to capture additional market opportunities in precision medicine.